ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO579

Hyperparathyroidism Helps to Explain the Disagreement Between Bioimpedance and Dual-Energy Absorptiometry in the Analysis of Nutritional Status

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical


  • Crispilho, Shirley Ferraz, Universidade Nove de Julho, São Paulo, Brazil
  • de Sa C. Filho, Eduardo J. Duque, Universidade de Sao Paulo, Brazil, SÃO PAULO, Brazil
  • Bezerra de carvalho, Kalyanna Soares, Universidade de Sao Paulo, Brazil, SÃO PAULO, Brazil
  • Pereira, Rosa M., Universidade de Sao Paulo, Brazil, SÃO PAULO, Brazil
  • Jorgetti, Vanda, Universidade de Sao Paulo, Brazil, SÃO PAULO, Brazil
  • Elias, Rosilene M., Universidade de Sao Paulo, Brazil, Brazil
  • Moyses, Rosa M.A., Universidade de Sao Paulo, Brazil, SÃO PAULO, Brazil

Body composition is critical in the evaluation of patients with CKD and can be obtained from multifrequency bioelectrical impedance analysis (BIA) or from the gold standard dual-energy absorptiometry (DXA). Previous studies have shown disagreements between these two methods, mainly regarding the bone mineral content (BMC). We hypothesized that secondary hyperparathyroidism, which is associated with bone loss, is the main responsible for this discrepancy.


We studied 20 pre-dialysis CKD patients (CKD) and 29 on hemodialysis (18 with severe hyperparathyroidism (HD-SHPT) and 11 already submitted to parathyroidectomy at least 1 year before our analysis (HD-PTX). The total-body composition was determined using DXA and BIA.


HD-SHPT patients tended to be younger (CKD = 52.5 ± 14.3 ys.; HD-SHPT = 41.6 ± 14.9 ys.; HD-PTX 44.9 ± 13.4 ys.; p = 0.06), but had lower BMC measured through DXA (CKD = 2,266 ± 565 g; HD-SHPT = 1,808 ± 522 g; HD-PTX 2,301 ± 658 g; p = 0.04). This difference was not found in BMC measured by BIA (CKD = 3,011 ± 596 g; HD-SHPT = 2,896 ± 711 g; HD-PTX 2,650 ± 467 g; p = 0.30).The highest disagreement between DXA and BIA was found in HD-SHPT group (CKD = -711 g; HD-SHPT = - 915 g; HD-PTX -688 g; p = 0.004). There was a significant correlation between the difference of BMC obtained from DXA and BIA with parathormone (PTH; r = -0.394; p = 0.006) and alkaline phosphatase (AP; r = -0.489; p < 0.0001).


Our results confirm that BIA should be interpreted cautiously in patients with SHPT since higher PTH and AP lead to a greater disagreement between these methods. Moreover, the recovery of bone mass and the decrease of the disagreement after PTX support our hypothesis. BIA loss of accuracy occurs because BMC is not measured, but obtained from an algorithm derived from normal individuals, using the fat-free mass values. Therefore, BMC overestimation is associated with an underestimation of lean mass. This misinterpretation might compromise the management of the nutritional status, as well as of the bone disease, in SHPT patients.


  • Government Support - Non-U.S.